Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.37	$3.31	$2.70 ▼ $4.72	$646.03M	0.86	636,487 shs	762,402 shs
CO Global Cord Blood	$0.55	$1.01	$2.03 ▼ $5.50	$66.85M	0.16	216,519 shs	1 shs
CORBF Global Cord Blood	$0.55	$0.98	$0.25 ▼ $2.00	$66.85M	-0.6	100,435 shs	1 shs
MRAI Marpai	$1.44 +2.9%	$1.34	$0.40 ▼ $1.68	$24.87M	4.66	16,534 shs	25,815 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	-0.88%	+7.67%	+9.42%	-8.42%
CO Global Cord Blood	0.00%	-59.26%	-26.67%	-47.62%	-68.57%
CORBF Global Cord Blood	0.00%	-59.26%	-26.67%	-47.62%	-68.57%
MRAI Marpai	+2.86%	+7.46%	+4.35%	+19.01%	+128.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.6192 of 5 stars	3.5	1.0	0.0	0.0	3.1	2.5	0.6
CO Global Cord Blood	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CORBF Global Cord Blood	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRAI Marpai	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	63.20% Upside
CO Global Cord Blood	0.00	N/A	N/A	N/A
CORBF Global Cord Blood	0.00	N/A	N/A	N/A
MRAI Marpai	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CO, CORBF, MRAI, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	104.70	N/A	N/A	$0.43 per share	7.84
CO Global Cord Blood	$1.24B	0.05	$0.13 per share	4.19	$6.34 per share	0.09
CORBF Global Cord Blood	$196.12M	0.34	$0.39 per share	1.40	N/A	∞
MRAI Marpai	$34.87M	0.71	N/A	N/A	($1.72) per share	-0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	N/A
CO Global Cord Blood	$79.04M	$0.64	0.86	∞	N/A	N/A	N/A	N/A	N/A
CORBF Global Cord Blood	$79.04M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MRAI Marpai	-$28.75M	-$0.87	N/A	∞	N/A	-85.70%	N/A	-100.23%	N/A

Latest CO, CORBF, MRAI, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CO Global Cord Blood	$0.08	14.55%	N/A	12.50%	N/A
CORBF Global Cord Blood	N/A	N/A	N/A	N/A	N/A
MRAI Marpai	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
CO Global Cord Blood	N/A	N/A	N/A
CORBF Global Cord Blood	N/A	N/A	N/A
MRAI Marpai	N/A	0.82	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CO Global Cord Blood	N/A
CORBF Global Cord Blood	N/A
MRAI Marpai	49.75%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
CO Global Cord Blood	0.50%
CORBF Global Cord Blood	0.50%
MRAI Marpai	46.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
CO Global Cord Blood	1,202	121.55 million	N/A	No Data
CORBF Global Cord Blood	1,200	121.55 million	N/A	Not Optionable
MRAI Marpai	150	17.27 million	5.61 million	No Data

CO, CORBF, MRAI, and ABUS Headlines

Recent News About These Companies

Marpai, Inc. Reports Significant Q2 2025 Turnaround

August 14 at 12:15 AM | tipranks.com

Marpai, Inc. (MRAI) Q2 2025 Earnings Call Transcript

August 14 at 10:05 AM | seekingalpha.com

MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

August 13 at 4:19 PM | prnewswire.com

MARPAI TO HOST WEBCAST ON AUGUST 14, 2025 TO DISCUSS SECOND QUARTER 2025 FINANCIAL RESULTS

August 7, 2025 | prnewswire.com

Marpai (NASDAQ:MRAI) Stock Price Down 0.7% - Time to Sell?

August 6, 2025 | americanbankingnews.com

MARPAIRX REVOLUTIONIZES PHARMACY BENEFITS WITH UNPRECEDENTED TRANSPARENCY AND SAVINGS

July 24, 2025 | prnewswire.com

Earnings call transcript: Marpai posts improved Q1 2025 results amid cost cuts

May 17, 2025 | uk.investing.com

Marpai, Inc. Reports Q1 2025 Financial Results

May 15, 2025 | tipranks.com

Marpai targets cash flow positivity in 2025 with cost reductions and leadership changes

May 15, 2025 | msn.com

Marpai, Inc. (MRAI) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

Marpai appoints new COO to accelerate growth

May 15, 2025 | uk.investing.com

MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

May 14, 2025 | prnewswire.com

MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

May 13, 2025 | prnewswire.com

Market Access RICI Agriculture UCITS (MRAI)

May 8, 2025 | investing.com

MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

May 7, 2025 | prnewswire.com

Marpai, Inc. to Present at the Planet MicroCap Showcase Las Vegas

April 15, 2025 | prnewswire.com

Marpai targets profitability in 2025 with new initiatives and strategic partnerships

March 27, 2025 | msn.com

Marpai, Inc. (MRAI) Q4 2024 Earnings Call Transcript

March 27, 2025 | seekingalpha.com

MARPAI REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

March 26, 2025 | prnewswire.com

MARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

March 20, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CO, CORBF, MRAI, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.37 0.00 (0.00%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.32 -0.06 (-1.63%)

As of 08/15/2025 07:59 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Global Cord Blood NYSE:CO

$0.55 0.00 (0.00%)

As of 08/14/2025

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

Global Cord Blood NYSE:CORBF

$0.55 0.00 (0.00%)

As of 08/14/2025

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Marpai NASDAQ:MRAI

$1.44 +0.04 (+2.86%)

As of 08/15/2025 03:52 PM Eastern

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time